Transkaryotic Therapies Replagal
Executive Summary
BLA submitted June 16 for Fabry disease enzyme replacement injectable agalsidase alfa based on Phase II data. The biologic has orphan drug designation and will receive priority review
You may also be interested in...
TKT European Company To Be Led By Ex-P&U Genotropin Team
Transkarayotic Therapies' newly established European company will be headed by executives who led the EU and Japan launch of Pharmacia & Upjohn's Genotropin.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011